• Explore /
  • Poster
  • / Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis.

Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis.

Abstract Poster

Authors

null

Milind M. Javle

University of Texas MD Anderson Cancer Center, Houston, TX;

Milind M. Javle , Christos Fountzilas , Daneng Li , Lionel Aurelien Kankeu Fonkoua , Jean Fan , Peng Peng , Hui Wang , Brenda Ngo , Caixia Sun , Qinhua Cindy Ru , Frank Wu , Amit Mahipal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04919642

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 539)

DOI

10.1200/JCO.2023.41.4_suppl.539

Abstract #

539

Poster Bd #

C9

Abstract Disclosures

Similar Posters

First Author: Junji Furuse

First Author: Milind M. Javle

First Author: Milind M. Javle

First Author: Do-Youn Oh